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1 Live attenuated influenza vaccine (LAIV) is in use
in Russia for decades and since 2003 in the United
States of America. The Russian LAIV is based on the
master donor viruses (MDVs) A/Leningrad/
134/17/57 (H2N2) and B/USSR/60/69 which are
coldadapted, temperature sensitive and attenuated
[1, 6, 8]. LAIV has a long record of being safe and effi
cacious. The safety of LAIV is guaranteed by its cold
adapted, temperature sensitive and attenuated pheno
type which limits viral replication to the upper respira
tory tract where the vaccine is administered. Efficacy
is achieved by induction of local and systemic humoral
and cellular immune responses accomplished by mim
icking natural infection.
The segmented nature of the influenza virus
genome enables exchange of each of eight gene seg
ments between two viruses following dual infection.
This process is referred to as reassortment and the
resulting viruses are called reassortant viruses. Reas
sortment is exploited in generating attenuated vaccine
viruses to be used in LAIV. Circulating wild type influ
enza A or B virus recommended by WHO for use in
1 The article was translated by the authors.
current epidemic season as vaccine candidates are co
infected with MDVs. The sole one of interest is a so
called 6 : 2 reassortant virus which contains the gene
segments encoding the surface glycoproteins—
haemagglutinin (HA) and neuraminidase (NA)—of
the wild type virus to be represented in the vaccine
while the remaining gene segments, which encode the
internal viral proteins, including those conferring
attenuation, must originate from the MDV.
Two coldadapted viruses, A/Leningrad/134/
17/57 (H2N2) and B/USSR/60/69, were generated in
1960s–1970s in the Department of Virology named by
Acad. A. A. Smorodintsev (Institute of Experimental
Medicine, NorthWest Division of the Russian Acad
emy of Medical Sciences) and now they are the only
MDVs approved in Russia for development of Russian
live attenuated influenza vaccine strains.
Coinfections typically yield numerous genetically
different viruses. Indeed, theoretically a total of 256
(28) different combinations of gene segments and,
consequently, an equal number of different viruses
may arise following coinfection. To diminish the
number of undesired reassortant viruses arising during
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co–infection, antiserum raised against the MDV and
low temperature of incubation are being used in subse
quent selective passages. Since time to generate vac
cine viruses is limited and only 6 : 2 reassortant viruses
are acceptable for inclusion in LAIV, a rapid, unam
biguous and reliable method to screen reassortant
viruses is of utmost importance.
Here, we describe RTPCR methods using gene
segment and virus (sub)type specific primers allowing
for rapid and unequivocal screening of reassortant
influenza A and influenza B viruses to be used in sea
sonal and pandemic LAIV.
MATERIALS AND METHODS
Viruses. Influenza wild type viruses were obtained
from CDC (Atlanta, GA) and from the National Insti
tute for Biological Standards and Control (NIBSC,
Potters Bar, UK). The MDVs A/Leningrad/134/17/57
(H2N2) and B/USSR/60/69 were obtained from the
Institute of Experimental Medicine (Saint Petersburg,
Russia). Viruses were propagated in 10 to 11 day old
embryonated hen’s eggs. Reassortant viruses were gen
erated by routine technique in embryonated chicken
eggs or Madin–Darby Canine Kidney (MDCK) cells
(ATCC, Cat. No. CCL34) as described in [18].
Briefly, equal doses of MDV and wild type virus were
inoculated into eggs or cells and incubated at optimum
temperature of 32°C (coinfection). The development
of vaccine reassortants involved sequential passages of
reassortant progeny at 25°C in the presence of antise
rum to MDV and by limit dilution cloning in the pres
ence of antiserum to MDV.
RNA isolation. RNA was isolated from influenza
virus infected allantoic fluid or cell culture superna
tant using the QIAamp Viral RNA Minikit according
to the manufacturer’s instructions (Qiagen GmbH,
Hilden, Germany).
cDNA synthesis. cDNAs were synthesized using
commercially available Quantitect Reverse Transcrip
tion Kit according to the manufacturer’s instructions
(Qiagen GmbH, Hilden, Germany). For cDNA syn
thesis universal primers were used so that in a single
reaction cDNAs were generated for all eight gene seg
ments. These cDNAs were used as templates in the
PCRs. The universal forward primer (Invitrogen) used
for influenza A viruses was AUNIVERSALF (5'TCGA
CGTCTCAGGGAGCAAAAGCAGG). The univer
sal forward primer (Invitrogen) used for influenza B
viruses was BUNIVERSALF (5'ACGTTGCAAGCA
GAAGC). The thermal cycler program for the reverse
transcription (RT) reaction was as follows: 42°C for
2 min: (put on ice while adding next step): 42°C for
15 min: 95°C for 3 min.
Design of PCR programs and selection of primers
for screening of reassortant influenza A and B viruses.
PCR programs and primers were designed such that
clear PCR products were obtained for the gene seg
ments of one of the parental viruses used in coinfec
tion (MDV or wild type virus) while under the same
PCR conditions and using the same primers no PCR
products were obtained for the other parental virus.
Gene segment and virus (sub)type specific primers
were selected in such a way that PCR products of dif
ferent sizes are obtained for wild type virus and MDV
specific primers and that wild type virus specific prim
ers do not amplify MDV gene segments and vice versa.
Twelve PCR programs that were used for genotyping of
reassortant viruses in order to select 6 : 2 vaccine
viruses are presented in Table 1. Sequences of each of
the gene segments of wild type influenza A viruses as
well as wild type influenza B viruses were aligned with
those of the MDVs A/Leningrad/134/ 17/57 (H2N2)
and B/USSR/60/69, respectively.
Sequences of wild type viruses were obtained from
sequence databases (http://www.flu.lanl.gov and
http://www.ncbi.nlm.nih.gov/genomes/FLU/Database/
select.cgi). Multiple sequence alignment analysis was
performed using Clone Manager 9.
PCR and gel electrophoresis. PCRs were carried
out in Eppendorf Master Cycler® gradient. Amplified
products were detected by 0.5 µg/mL ethidium bro
mide staining of amplified products after 1.7% agarose
gel electrophoresis.
All reagents were obtained from SibEnzime
(Novosibirsk, Russia).
RESULTS AND DISCUSSION
Because of high antigenic variability of influenza
viruses, the composition of influenza vaccines for use
in each influenza season is changed annually. This
means that for LAIV, vaccine strains have to be made
annually as well by classical reassortant techniques.
Selection and screening of reassortant viruses for their
genetic makeup preferably has to be convenient and
rapid. Therefore, time for screening and characteriza
tioin of reassortant vaccine strains for any new epi
demic season is limited; the efficacy of development of
vaccine depends on the method of identification and
analyses of its genome composition. The final step of
screening modern live influenza vaccine candidates is
full genetic sequencing, but at the intermediate steps
when a large number of reassortant viruses have to be
urgently analyzed there is need for a rapid and reliable
method of primary screening.
Determination of the origin of gene segments in
reassortant influenza viruses can be done using several
techniques. Polyacrylamide gel electrophoresis of viral
176
MOLECULAR GENETICS, MICROBIOLOGY AND VIROLOGY  Vol. 26  No. 4  2011
KISELEVA et al.
RNA was a popular assay in the 1980s [10, 11, 13, 15].
However, this technique is laborious and time consum
ing. With respect to polyacrylamide gel electrophoresis,
migration patterns of RNAs derived for MDV and wild
type virus may be difficult to distinguish.
An alternative approach is the use of multiplex RT
PCRs that yield a yes/no result [4, 5, 9]. This method
is currently in use both for typing of influenza A and B
viruses, subtyping of influenza A virus and for screen
ing of reassortant live influenza vaccine virus strains.
In brief, primers are selected that specifically amplify
the genes encoding the internal proteins of the MDV
and the surface glycoproteins HA and NA of the wild
type virus. By optimizing the primers and PCR condi
tions, multiple primer sets can be mixed and more
than one PCR reaction can be run in a single tube. The
authors were able to determine the origin of all eight
gene segments of reassortants in a total of three PCR
reactions which allows for screening of numerous
viruses in a relatively short period of time. However,
using the multiplex PCRs no answer can be given
about cleanliness of the reassortant virus. It cannot be
ruled out that the reassortant virus is contaminated
with another reassortant virus containing one or more
wild type virus gene segments as these are not detected
in their PCRs. The multiplex PCR definitely is attrac
tive for initial screening, but needs additional PCRs or
sequencing to rule out contamination with other reas
ssortant viruses containing wild type gene segments.
One of the most reliable method is RTPCR fol
lowed by digestion of PCR products with restriction
enzymes (Restriction Fragment Length Polymor
phism or RFLP) [2, 3, 7, 12, 14, 17]. RFLPs reveal
differences in sequences of RNA segments as well as
by different lengths of the restriction fragments pro
duced by enzymatic digestion of a selected region of
gene. Digested products are detected by ethidium bro
mide staining after agarose gel electrophoresis. With
respect to RFLP, the use of restriction enzymes has
several specific disadvantages, for instance, restriction
enzymes may not always fully cut a PCR product,
which complicates the determination of the origin of
Table 1. Programs for comparative PCR analysis of genome composition of reassortants of master donor viruses with wild
type viruses
Pro
gram 
code
Preheating
PCR main stages
PostPCR
Melting Annealing Polymerization
No. of 
cyclestime, 
min temp, °C time, s temp, °C time temp, °C
time, 
min temp, °C
time, 
min temp, °C
1 4 94 30 94 30 s 55 1 68 30 7 68
2 4 94 30 94 30 s 60 1 72 30 7 72
3 4 94 30 94 30 s 63 1 72 30 7 72
4 4 94 30 94 30 s 55 1 72 30 7 72
5 4 94 30 94 1 min 55 1 68 45 7 68
6 4 94 30 94 1 min 55 1 68 30 7 68
7 4 94 30 94 1 min 63 1 68 30 7 68
8 4 94 30 94 1 min 61 1 68 45 7 68
9 4 94 30 94 1 min 50 1 68 45 7 68
10 4 94 30 94 1 min 61 1 68 30 7 68
11 4 94 30 94 1 min 50 1 68 30 7 68
12* 4 94 30 94 30 sec 48 1 72 20 7 72
Note: Gradient PCR program (start temperature 53°C, end temperature 48°C; 0.5°C decrease per cycle; 11 cycles from start to the end).
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(e) (f) (g) (h)
Fig. 1. PCRidentification of the genome composition of a reassortant virus obtained from coinfection of the A/Lenin
grad/134/17/57 (H2N2) master donor virus and the A/Brisbane/10/2007 (H3N2) seasonal influenza virus.
On the top of panels—virus specific primers: H3—specific primers to A (H3N2) seasonal influenza viruses; Н2—specific primers
to A/Leningrad/134/17/57 (H2N2) master donor virus. On the bottom of panels—tested viruses: 1—reassortant virus; 2—
A/Leningrad/134/17/57 (H2N2) master donor virus; 3—A/Brisbane/10/2007 (H3N2) seasonal influenza virus; 4—A/Bris
bane/59/2007 (H1N1) seasonal influenza virus; M—molecular weight marker; (a)—PB2 gene; (b)—PB1 gene; (c)—РА gene;
(d)—НА gene; (e)—NP gene; (f)—NA gene; (g)—M gene; (h)—NS gene.
gene segments of reassortants. Incomplete digestion
may result from insufficient enzyme activity or could
indicate that the virus is not clean.
The aim of this study was to design a PCR method
using gene segment and virus (sub) type specific prim
ers allowing for rapid and unequivocal screening of
reassortant influenza A and influenza B viruses to be
used in seasonal and pandemic LAIV.
Seasonal influenza A (H1N1 and H3N2) virus spe
cific primers. Virus subtype specific primer sets were
designed for each of the gene segments of wild type
seasonal influenza A H1N1 virus and the A/Lenin
grad/134/17/57 (H2N2) MDV (Tables 2, 3). H1N1 or
H3N2 specific primers only yielded PCR products for
gene segments derived from H1N1 or H3N2 virus
respectively, while MDV specific primers only yielded
PCR products for MDV derived gene segments. More
over, the PCR product obtained with wild type virus
specific primers differed in size from the PCR product
obtained with MDV specific primers. Thus, the yes/no
result and the difference in size make it easy to dis
criminate the PCR products on gel and to determine
the origin of each of the gene segments in a reassortant
virus.
An example is shown in Fig. 1. As can be seen in
this figure, reassortant possessed HA and NA from
A/Brisbane/10/2007 (H3N2) wild type virus, which
was in use for vaccine production in the 2009–2010
influenza season. Vaccine candidate virus yielded
PCR products for HA (Fig. 1d) and NA (Fig. 1f) using
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H1
1 2 3M 4 3 2 1 3 1 2 M 4 5 3M 1 3 5 4 4 3 5 M
(a) (b)
H2 H1 + H2 H3 H2 H3 + H2
Fig. 2. Mixed PCR analysis of haemagglutinin gene segment belonging to A (H1N1), A (H3N2) or A (H2N2) influenza virus.
On the top of panels—tested viruses: Н1—A/Brisbane/59/2007 (H1N1) seasonal influenza virus; H2—A/Leningrad/134/17/57
(H2N2) master donor virus; H1 + H2—mixture of A/Brisbane/59/2007 (H1N1) with A/Leningrad/134/17/57 (H2N2) viruses;
H3—A/Brisbane/10/2007 (H3N2) seasonal influenza virus; H3 + H2—mixture of A/Brisbane/10/2007 (H3N2) with A/Le
ningrad/134/17/57 (H2N2) viruses. On the bottom of panels—virus specific primers to influenza virus haemagglutinin: 1—spe
cific primers to A (H1N1) seasonal influenza viruses; 2—mixture of specific primers to A (H1N1) seasonal influenza viruses with
specific primers to A/Leningrad/134/17/57 (H2N2) master donor virus; 3—specific primers to A/Leningrad/134/17/57 (H2N2)
master donor virus; 4—specific primers to A (H3N2) seasonal influenza viruses; 5—mixture of specific primers to A (H3N2)
seasonal influenza viruses with specific primers to A/Leningrad/134/17/57 (H2N2) master donor virus; M—molecular weight
marker. Left panel (a)—distinguishing haemagglutinin gene segment of A (H1N1) seasonal influenza virus from those of A/Le
ningrad/134/17/57 (H2N2) master donor virus. Right panel (b)—distinguishing haemagglutinin gene segment of A (H3N2) sea
sonal influenza virus from those of A/Leningrad/134/17/57 (H2N2) master donor virus.
H3N2 specific primers but not when MDV specific
primers were used). Contrary, the reassortant H3N2
virus yielded PCR products using MDV specific prim
ers for PB2 (Figure 1a), PB1 (Fig. 1b), PA (Fig. 1c),
NP (Fig. 1e), M (Fig. 1g) and NS (Fig. 1h) gene seg
ments but no PCR products were obtained using
H3N2 specific primers, clearly demonstrating that the
six gene segments encoding the internal viral proteins
all originated from MDV.
Mixed RTPCR. For the determination of the ori
gin of the HA and NA encoding gene segments, so
called mixed PCRs were developed whereby in a single
reaction MDV and wild type seasonal influenza A
(H1N1 or H3N2) specific primers were used. The
primers were selected in different regions of the gene
segments resulting in different sizes of PCR products
obtained for MDV and wild type virus.
An example is shown in Fig. 2. As can be seen in the
left panel (Fig. 2a), H1N1 virus yields a PCR product
with H1 specific primers and a mixture of PCR prod
uct with H1 and H2 (MDV) specific primers, but not
with H2 or H3 specific primers alone. Contrary, MDV
yields a PCR product using H2 specific primers and a
mixture with H1 and H2 specific primers, but not with
H1 specific primers alone. Since the size of the PCR
product obtained with the H1 specific primers differs
from that obtained with H2 specific primers, the
mixed H1/H2 PCR can be used to easily determine
the virus subtype in a single PCR reaction. In case of a
mixture of two different subtypes, two clearly sepa
rated PCR products are obtained in this mixed PCR.
Thus, in the event that the serum used during selective
passages following coinfection is not completely
blocking viruses containing the haemagglutinin of
MDV, this will be clearly visible in the mix PCR. Anal
ogous to the H1/H2 mixed PCR, a H3/H2 mixed PCR
was developed to distinguish wild type and reassortant
H3 viruses from H2 viruses (right panel, Fig. 2b).
In addition to the mixed PCR for determination of
the origin of HA, a mixed PCR was developed to dis
tinguish neuraminidase N1 from N2. As can be seen in
Fig. 3, A/Brisbane/59/2007 (H1N1) virus, yields a
PCR product with N1 specific primers or a mixture
with N1 and N2 specific primers but not with N2
(MDV) specific primers. The opposite is found for
MDV. As with the H1/H2 mixed PCR, a mixture of
two viruses will easily be detected as two bands of dif
ferent size will appear in gel electrophoresis.
Screening of reassortant viruses in this way yielded
unambiguous results. Indeed, for each individual gene
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Fig. 3. Mixed PCR analysis of neuraminidase gene segment belonging to A (H1N1) or A (H2N2) influenza virus.
On the top of panel—tested viruses: H1—A/Brisbane/59/2007 (H1N1) seasonal influenza virus; H2—A/Leningrad/134/17/57
(H2N2) master donor virus; H3—A/Brisbane/10/2007 (H3N2) seasonal influenza virus; H1 + H2—mixture of A/Bris
bane/59/2007 (H1N1) with A/Leningrad/134/17/57 (H2N2) viruses; + H2—mixture of A/Brisbane/10/2007 (H3N2) with
A/Leningrad/134/17/57 (H2N2) viruses. On the bottom of panels—virus specific primers to influenza virus neuraminidase: 1—
specific primers to A/Leningrad/134/17/57 (H2N2) master donor virus; 2—specific primers to neuraminidase of A (H1N1) sea
sonal influenza viruses; 3—mixture of specific primers to A/Leningrad/134/17/57 (H2N2) master donor virus and A (H1N1)
seasonal influenza viruses; М—molecular weight marker. 
segment of both the MDV and the wild type parental
viruses, PCR products of different sizes were obtained
with MDV and wild type virus specific primer sets,
respectively. Using the primers the other way around
(MDV with wild type virus specific primers and wild
type virus with MDV specific primers) no PCR prod
ucts were obtained. When reassortant viruses are ana
lyzed in this way, the genome composition will imme
diately be clear and, importantly, will demonstrate
whether or not the virus is of a single genotype. In case
of a mixture of two or more genetically different
viruses this will become clear by the appearance of two
different sized PCR products for one or more gene
segments. This demonstrates that the mixed PCR
assay is very specific and may also be used for typing of
influenza A and B isolates from influenza patients and
from individuals vaccinated with LAIV.
Seasonal influenza B virus specific primers. Regions
of naturally occurring sequence diversity between cur
rently circulating wild type influenza B viruses and the
B/USSR/60/69 MDV were identified to design gene
segment specific primer sets analogous to wild type
influenza A viruses and A/Leningrad/134/17/57
(H2N2) MDV (Table 4).
Pandemic and prepandemic influenza A (H1N1 and
H5N1) virus specific primers. In 2009, a novel H1N1
virus appeared that rapidly spread around the globe
resulting in the first influenza pandemic of 21st cen
tury. This H1N1 virus (of which A/California/07/09
(H1N1) is an example) is quite different from the
H1N1 virus that circulated previously. Therefore, new
primers were designed that allowed for discrimination
of gene segments of this novel H1N1 virus from those
of MDV (Table 5).
Today both circulating H1N1 Californialike influ
enza viruses of swine origin and highly pathogenic A
(H5N1) avian influenza viruses still confer a potential
influenza pandemic risk. The use of highly pathogenic
influenza viruses with pandemic potential in the gen
eration of vaccine viruses to be used in LAIV is undes
ired from an operator safety point of view. In these
cases alternatives are to be sought for donation of the
proper surface glycoproteins of A (H5N1) avian influ
enza virus in an MDV backbone. The use of reassor
tant viruses based on A/PR/8/34 (H1N1) could be an
alternative to wild type virus. A/PR/8/34 (H1N1) is
routinely used for generating high yield reassortant
influenza A viruses for inactivated influenza vaccines
including H5N1. In this case, the HA of the H5N1
virus was first modified by removal of the multibasic
cleavage site to make haemagglutinin apathogenic.
Than modified HA together with NA were put in a
background of A/PR/8/34 (H1N1) using reverse
genetics [16]. These H5N1–PR8 based reassortant
viruses produced by NIBSC (UK) and CDC (USA)
could well be used in coinfections with coldadapted
MDV to generate new reassortant viruses. Replace
ment of PR8 internal genes in the genome of H5N1–
PR8 based reassortants with appropriate genes of
MDV will lead to the generation of a prepandemic
LAIV candidate. Also for these situations, primers
were designed that enabled discrimination between six
internal gene segments derived from MDV or
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A/PR/8/34 (H1N1) virus, and HA and NA derived
from MDV and H5N1 virus, respectively (Table 6).
In conclusion, RTPCRs were developed that
unambiguously demonstrate the genome composition
of A and B reassortant influenza viruses. These RT
PCRs allow for the clear and rapid selection of both
influenza A and influenza B vaccine viruses (6 : 2 reas
sortant viruses) to be used in LAIV production.
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